Navigation Links
AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
Date:9/22/2008

WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April 1, 2009. AstraZeneca has been working with the FDA in the investigation of the safety and effectiveness of CASODEX in a pediatric setting but will not be seeking an indication in this population.

CASODEX is currently approved in the US at a dose of 50 mg daily tablet for use in combination with a luteinizing hormone-releasing hormone analog (LHRH-A) for the treatment of advanced prostate cancer (metastatic Stage D2).

AstraZeneca has a well-established prostate cancer portfolio including hormonal treatments CASODEX, launched in 1995, and ZOLADEX(R) (goserelin acetate implant), launched in 1989. Three Phase III clinical research trials (ENTHUSE program) are currently underway to evaluate the safety and effectiveness of an investigational compound, ZD4054, in non-metastatic and metastatic hormone-resistant prostate cancer.

About Prostate Cancer

Over 186,000 men will be diagnosed with prostate cancer in the U.S. in 2008, making it the most frequently diagnosed cancer in men.(1) After lung cancer, prostate cancer is the second leading cause of cancer death in men, with an estimated 28,660 deaths in 2008.(2) One in six men will develop prostate cancer in his lifetime.

About CASODEX(R) (bicalutamide) Tablets

CASODEX at a dose of 50 mg daily is a prescription medication approved for use in combination with an injection of a luteinizing hormone-releasing hormone analog (LHRH-A) for treatment of advanced prostate cancer (metastatic Stage D2).

CASODEX at a dose of 150 mg daily is not approved for use alone or with other treatments. See full Prescribing Information under the section on "CLINICAL PHARMACOLOGY-Clinical Studies-Safet
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
2. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
3. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
4. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
5. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
6. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
9. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
10. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
11. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...OMINGTON, Minn, Nov. 27 ACUO TECHN...age management software, data migration tools and ...tates Patent and Trademark Office has approved a p...at within a Computer Network." Acuo Technologies i...of intellectual property. In general, the granted ...
(Date:11/26/2009)...ESBURG,SouthAfrica,Nov.26/PRNewswire/--The2009Fros...eGenericPharmaceuticalMarketispresentedtoCiplaMedp...com.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Forth...dtobenchmarkCiplaMedpro,sperformanceagainstkeycomp...novationinbusinessprocesses,productsand/ortechnolo...
(Date:11/25/2009)..., WESTON, Fla., Nov. 25 /PRNewswire-FirstCall/ -... ASFX) ("the Company") is pleased to announce that...ion management office in Shanghai, China. ,, AS...ding an essential gateway for the development and ... products for children and adults to be distribute...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3American Scientific Resources Inc. Opens Shanghai Location 2Inc Magazine Names Enovate as One of the Fastest Growing Private Companies in the US 54707 1Inc Magazine Names Enovate as One of the Fastest Growing Private Companies in the US 54707 2Inc Magazine Names Enovate as One of the Fastest Growing Private Companies in the US 54707 3NEHA Housekeeping Channel Partnership to Improve Home Cleanliness and Health 54705 1NEHA Housekeeping Channel Partnership to Improve Home Cleanliness and Health 54705 2NEHA Housekeeping Channel Partnership to Improve Home Cleanliness and Health 54705 3H1N1 Flu 28Swine Flu 29 Fears What People Can Do to Ease Them According to GLT Enviro 54703 1H1N1 Flu 28Swine Flu 29 Fears What People Can Do to Ease Them According to GLT Enviro 54703 2H1N1 Flu 28Swine Flu 29 Fears What People Can Do to Ease Them According to GLT Enviro 54703 3
...RX1023 Shows Promising Results, GAITHERSBURG, Md....al scientific data for VRX1023 today at the Keysto...is part of a new vaccine approach --,using HIV-bas...tigen,expressing lentiviral vector, has produced p...an primate studies. A larger, confirmatory study i...
...ON, Mass., March 28 Use of,a low profile Pressure...ion,pressure gradients when compared to catheter-d...ding to a paper published in the Journal of,Interv...)., The authors report that although CPG measurem... correlated with anatomic stenosis, PressureWire,g...
Other Medicine Technology:VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 3
(Date:11/27/2009)...27 The Gymboree Corporat... CFO/COO, will present at the NASDAQ OMX 23rd Inve...otel in London, England, on Wednesday, December 2,...e broadcast of The Gymboree Corporation,s presenta...ree.com, click on "Our Company" at the bottom of t...
(Date:11/27/2009)...el, Nov. 27 Shamir Optic...leading provider of innovative products and techno...y that its board of directors had declared a divid...million (approximately NIS 37.62 million based on ...nge), or approximately US$ 0.609 (approximately NI...
(Date:11/27/2009)...ented medical, economic burdens, study predicts ,...e number of people with diabetes in the United Sta...a new study predicts. , That would bring the to...disease, up from 23.7 million today. , , At the ...es will triple, the study also warns, rising from ...
(Date:11/27/2009)...-purpose bilingual coloring books designed for chi...ss community to educate - inform parents and child...ues to Dinosuars to ABC,S and a host of other topi...WEB) November 27, 2009 -- Today’s children h...em busy any hour of the day, but one of the oldest...
(Date:11/26/2009)...PRNewswire/ -- With cold and flu season upon us, i...ces to control the spread of infections and avoid ...o keep ourselves healthy, but to avoid transmittin... MS, CIC (certified in infection-control), nursing...ealth at Hospital for Special Surgery (HSS) in Man...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...logies (OTC Bulletin Board: PSTX) today announced ...ptember 30, 2008. , "We are pleased to see t...re institutions across the U.S. translate into inc...incidents of retained,sponges, current and potenti...
...(OTC Bulletin Board: CLXS), a leading developer of... announced today the formal launch of the,Reviewer...he best reviewers,based on their research profile....g document Fingerprint is compared,against more th...
...e premier,transplant reference and consultative la...coska, a leading figure in the field of immunology...m of Laboratory Directors. , Dr. Pancoska ha...HLA Laboratory, Community Blood Center of Paramus ...
...., a wholly owned subsidiary of Mercury Computer S...elected by Beebe Medical Center to provide,its ent...eal-time medical,imaging. , Based in Lewes, ..., and restore optimal health to the people residin...
...ated (Nasdaq: WPCS ), a leader in design-build e...stems and wireless infrastructure, has announced,t...roximately $9 million in,new contracts. The contra...lege and CalPERS. , In addition, WPCS was se...
...wners know,the dilemma -- my dog is old and has he... should I know when to let him go to the big dog p...olorado fee-only financial planner, knows,the prob...the question: ,How do we know when it,s time?, the...
Other Medicine News:Health News:Patient Safety Technologies Reports Third Quarter 2008 Results 2Health News:Patient Safety Technologies Reports Third Quarter 2008 Results 3Health News:Patient Safety Technologies Reports Third Quarter 2008 Results 4Health News:Patient Safety Technologies Reports Third Quarter 2008 Results 5Health News:Patient Safety Technologies Reports Third Quarter 2008 Results 6Health News:Collexis Launches Innovative Reviewer Finder to Enhance the $30 Billion Health Research Grant Industry 2Health News:Collexis Launches Innovative Reviewer Finder to Enhance the $30 Billion Health Research Grant Industry 3Health News:LABS Inc. Adds Dr. Carol Pancoska as Laboratory Director 2Health News:Visage Imaging to Provide Enterprise-Wide Thin Client Solutions to Beebe Medical Center 2Health News:Visage Imaging to Provide Enterprise-Wide Thin Client Solutions to Beebe Medical Center 3Health News:Visage Imaging to Provide Enterprise-Wide Thin Client Solutions to Beebe Medical Center 4Health News:WPCS Announces $9 Million in New Contracts 2Health News:Author Pens Pet Guardian Self-Defense Manual 2
FLEXILOG 2000 Pouch and Belt
13848 Buffer Solution pH 4.00 (250ml)
FLEXILOG Trolley for Stationary System
Bravo Vacuum Pump
Medicine Products: